keyword
MENU ▼
Read by QxMD icon Read
search

Alum adjuvant

keyword
https://www.readbyqxmd.com/read/28933663/type-iii-hypersensitivity-reactions-to-a-b-cell-epitope-antigen-are-abrogated-using-a-depot-forming-vaccine-platform
#1
Lisa D MacDonald, Alecia MacKay, Valarmathy Kaliaperumal, Genevieve Weir, Andrea Penwell, Rajkannan Rajagopalan, Joanne Langley, Scott Halperin, Marc Mansour, Marianne M Stanford
Peptide antigens are combined with an adjuvant in order to increase immunogenicity in vivo. The immunogenicity and safety of a RSV vaccine formulated in a novel oil-based platform, DepoVax™ (DPX), was compared to an alum formulation. A peptide B cell epitope derived from RSV small hydrophobic ectodomain (SHe) served as the antigen. Both vaccines induced SHe-specific antibodies after immunization of mice. A single dose of the DPX-based formulation resulted in anti-SHe titres for up to 20 weeks. Boosting with Alum-SHe, but not with DPX-SHe, led to unexpected clinical signs such as decreased activity, cyanosis and drop in body temperature in mice but not in rabbits...
September 21, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28927819/effect-of-endotoxin-and-alum-adjuvant-vaccine-on-peanut-allergy
#2
Brandi T Johnson-Weaver, Susan McRitchie, Kelly A Mercier, Wimal Pathmasiri, Susan J Sumner, Cliburn Chan, Dori Germolec, Michael Kulis, A Wesley Burks, Herman F Staats
Environmental endotoxin and alum-adjuvanted vaccines did not influence peanut-allergy development in mice. Exposure to alum and CpG-adjuvanted vaccines indirectly reduced allergic disease severity. Fecal metabolites differentiated mice based on disease severity.
September 16, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28911033/formulation-of-chitosan-with-the-polyepitope-hiv-1-protein-candidate-vaccine-efficiently-boosts-cellular-immune-responses-in-mice
#3
Ehsan Ollah Jazaeri, Atiyeh Mahdavi, Asghar Abdoli
Human immunodeficiency virus-1 (HIV-1) continues to be a major global public health issue and priority. Despite the variety of antiretroviral therapies, it seems that an effective vaccine against HIV-1 is still very necessary. An ideal HIV-1 vaccine should be able to elicit both humoral and cellular immunities. In this respect, polyepitope vaccines, incorporated from several conserved regions of HIV-1 proteins, have received much attention recently. Herein, the immunogenicity of the HIV-1 polyepitope protein-based candidate vaccines was evaluated in BALB/c mice...
November 30, 2017: Pathogens and Disease
https://www.readbyqxmd.com/read/28906131/effects-of-immunomodulators-on-the-response-induced-by-vaccines-against-autoimmune-diseases
#4
Dante J Marciani
A promising treatment for T-cell-mediated autoimmune diseases is the induction of immune tolerance by modulating the immune response against self-antigens, an objective that may be achieved by vaccination. There are two main types of vaccines currently under development. The tolerogenic vaccines, composed of proteins formed by a cytokine fused to a self-antigen, which usually induce tolerance by eliminating the T-cells that are immune reactive against the self-antigen. The immunogenic vaccines, comprised of a self-antigen plus a sole Th2 adjuvant either free or conjugated, that alleviate autoimmunity by switching the immune response against the self-antigen, from a damaging pro-inflammatory Th1/Th17 to an anti-inflammatory Th2 immunity...
September 14, 2017: Autoimmunity
https://www.readbyqxmd.com/read/28868617/prophylactic-immunization-with-human-papillomavirus-vaccines-induces-oral-immunity-in-mice
#5
Julie Ahn, Shiwen Peng, Chien-Fu Hung, Richard B S Roden, Simon R Best
OBJECTIVE: Although it has been shown that prophylactic vaccination can induce genital immunity, there is inadequate information on human papillomavirus (HPV) vaccine-induced oral immunity, which is of particular interest due to HPV-associated oropharyngeal malignancies and recurrent respiratory papillomatosis. Therefore, we assessed the efficacy of various HPV vaccines against oral HPV pseudovirus (PsV) infection in mice. STUDY DESIGN: Preclinical scientific investigation...
September 4, 2017: Laryngoscope
https://www.readbyqxmd.com/read/28857243/immunogenicity-of-a-fusion-protein-containing-pilq-and-disulfide-turn-region-of-pila-from-pseudomonas-aeruginosa-in-mice
#6
Mehrdad Gholami, Alireza Salimi Chirani, Shabnam Razavi, Reza Falak, Gholamreza Irajian
Interference with bacterial adhesion is a new means to prevent or treat bacterial infections. In this experimental study we evaluated the immunogenic properties of a chimeric protein composed of PilQ and disulfide turn region of PilA from Pseudomonas aeruginosa in mice as an anti-adhesion based vaccine. First of all, a chimeric bivalent protein composed of PilQ and PilA was constructed and following subcutaneous immunization with merely the purified protein or in its admixed form with alum, the immunogenicity of the chimeric antigen was assessed in BALB/c mice...
August 31, 2017: Letters in Applied Microbiology
https://www.readbyqxmd.com/read/28855902/different-adjuvants-induce-common-innate-pathways-that-are-associated-with-enhanced-adaptive-responses-against-a-model-antigen-in-humans
#7
Wivine Burny, Andrea Callegaro, Viviane Bechtold, Frédéric Clement, Sophie Delhaye, Laurence Fissette, Michel Janssens, Geert Leroux-Roels, Arnaud Marchant, Robert A van den Berg, Nathalie Garçon, Robbert van der Most, Arnaud M Didierlaurent
To elucidate the role of innate responses in vaccine immunogenicity, we compared early responses to hepatitis B virus (HBV) surface antigen (HBsAg) combined with different Adjuvant Systems (AS) in healthy HBV-naïve adults, and included these parameters in multi-parametric models of adaptive responses. A total of 291 participants aged 18-45 years were randomized 1:1:1:1:1 to receive HBsAg with AS01B, AS01E, AS03, AS04, or Alum/Al(OH)3 at days 0 and 30 (ClinicalTrials.gov: NCT00805389). Blood protein, cellular, and mRNA innate responses were assessed at early time-points and up to 7 days after vaccination, and used with reactogenicity symptoms in linear regression analyses evaluating their correlation with HBs-specific CD4(+) T-cell and antibody responses at day 44...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28837693/alternative-vaccine-administration-by-powder-injection-needle-free-dermal-delivery-of-the-glycoconjugate-meningococcal-group-y-vaccine
#8
Nikolas T Weissmueller, Leanne Marsay, Heiko A Schiffter, Robert C Carlisle, Christine S Rollier, Robert K Prud'homme, Andrew J Pollard
Powder-injectors use gas propulsion to deposit lyophilised drug or vaccine particles in the epidermal and sub epidermal layers of the skin. We prepared dry-powder (Tg = 45.2 ± 0.5°C) microparticles (58.1 μm) of a MenY-CRM197 glyconjugate vaccine (0.5% wt.) for intradermal needle-free powder injection (NFPI). SFD used ultrasound atomisation of the liquid vaccine-containing excipient feed, followed by lyophilisation above the glass transition temperature (Tg' = - 29.9 ± 0.3°C). This resulted in robust particles (density~ 0...
2017: PloS One
https://www.readbyqxmd.com/read/28829599/nonpyrogenic-molecular-adjuvants-based-on-norabu-muramyldipeptide-and-norabu-glucosaminyl-muramyldipeptide-synthesis-molecular-mechanisms-of-action-biological-activities-in-vitro-and-in-vivo
#9
Roman Effenberg, Pavlína Turánek Knötigová, Daniel Zyka, Hana Čelechovská, Josef Mašek, Eliška Bartheldyová, Frantisek Hubatka, Štěpán Koudelka, Róbert Lukáč, Anna Kovalová, David Saman, Michal Křupka, Lucia Barkocziová, Petr Kosztyu, Marek Šebela, Ladislav Drož, Michal Hučko, Mária Kanásová, Andrew David Miller, Milan Raška, Miroslav Ledvina, Jaroslav Turanek
Apyrogenic fatty acyl analogues of muramyldipeptide (MDP) (abbreviated N-L18norAbuGMDP, N-B30norAbuGMDP, norAbuMDP-Lys(L18), norAbuMDP-Lys(B30), norAbuGMDP-Lys(L18), norAbuGMDP-Lys(B30), (B30)norAbuMDP, (L18)norAbuMDP) were designed and synthesized comprising the normuramyl-L-α-aminobutanoyl (norAbu) structural moiety. All new analogues show depressed pyrogenicity both as free compounds and in liposomal formulations when tested in vivo in rabbits (s.c. and i.v. application). The potency of analogues in selective activation of NOD2 and NLRP3 (inflammasome) receptors in vitro, but not NOD1, is demonstrated using transgenic cell-based detection systems...
August 22, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28828575/improving-the-efficacy-of-a-prophylactic-vaccine-formulation-against-lymphatic-filariasis
#10
Nikhil Chauhan, Priyankana Banerjee, Vishal K Khatri, Andrew Canciamille, Jessica Gilles, Ramaswamy Kalyanasundaram
Mass drug administration (MDA) is the current strategy for interrupting the transmission of lymphatic filariasis (LF) infection and control of the disease in endemic areas. However, subject non-compliance has resulted in the presence of several "transmission hotspots" in the endemic regions threatening the reemergence of LF. This situation is further complicated by the fact that the drugs used in MDA are not effective against adult LF worms, a major concern for the control strategy. Thus, there is clearly a need for an effective and sustainable approach to control LF...
August 21, 2017: Parasitology Research
https://www.readbyqxmd.com/read/28777067/schistosoma-mansoni-cercarial-elastase-smce-differences-in-immunogenic-properties-of-native-and-recombinant-forms
#11
Marwa H El-Faham, Katherine J Wheatcroft-Francklow, Helen P Price, Jon R Sayers, Michael J Doenhoff
The Schistosoma mansoni cercarial elastase (SmCE) has previously been shown to be poorly immunogenic in mice. However, a minority of mice were able to produce antibodies against SmCE after multiple immunizations with crude preparations containing the enzyme. These mice were partially protected against challenge infections of S. mansoni. In the present study, we show that in contrast to the poor immunogenicity of the enzymatically active native form of SmCE derived from a crude preparation (cercarial transformation fluid), immunization of CBA/Ca mice with two enzymatically inactive forms, namely purified native SmCE or a recombinant SmCE fused to recombinant Schistosoma japonicum glutathione S-transferase (rSmCE-SjGST), after adsorption onto aluminum hydroxide adjuvant, induced specific anti-SmCE immunoglobulin G (IgG) in all mice within 2 weeks of the second immunization...
September 2017: Parasitology
https://www.readbyqxmd.com/read/28767426/human-papillomavirus-16l1-58l2-chimeric-virus-like-particles-elicit-durable-neutralizing-antibody-responses-against-a-broad-spectrum-of-human-papillomavirus-types
#12
Xue Chen, Hongyang Liu, Zhirong Wang, Shuo Wang, Ting Zhang, Meili Hu, Liang Qiao, Xuemei Xu
The neutralizing antibodies elicited by human papillomavirus (HPV) major capsid protein L1 virus-like particle (VLP)-based vaccines are largely type-specific. An HPV vaccine inducing cross-neutralizing antibodies broadly will be cost-effective and of great value. To this end, we constructed HPV16L1-58L2 chimeric VLP (cVLP) by displaying HPV58 L2 aa.16-37 on the DE surface region of HPV16 L1. We found that vaccination with the HPV16L1-58L2 cVLP formulated with alum plus monophosphoryl lipid A (Alum-MPL) adjuvant elicited robust neutralizing antibodies in both mice and rabbits against all tested HPV types including HPV16/31/33/35/52/58 (genus α9), HPV18/39/45/59/68 (genus α7), HPV6/11 (genus α10), HPV2/27/57 (genus α4), and HPV5 (genus β1)...
July 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28754265/evaluation-of-prevalence-immunogenicity-and-efficacy-of-fyua-iron-receptor-in-uropathogenic-escherichia-coli-isolates-as-a-vaccine-target-against-urinary-tract-infection
#13
Mehri Habibi, Mohammad Reza Asadi Karam, Saeid Bouzari
Uropathogenic Escherichia coli (UPEC) are among the most prevalent agents of urinary tract infections (UTIs). Antibiotic resistance reaches the need for alternative treatment approaches such as vaccination against UTIs. There is no ideal vaccine against UTIs, thus there is a need to evaluate different targets of uropathogens against UTIs. Ferric scavenger receptor FyuA in UPEC has the properties of an ideal vaccine candidate against UTIs. In the present study, the prevalence of FyuA among UPEC isolates, its immunogenicity with and without alum adjuvant, and its efficacy against experimental UTI were assessed...
July 25, 2017: Microbial Pathogenesis
https://www.readbyqxmd.com/read/28741316/role-of-cd4-t-cell-helper-subsets-in-immune-response-and-deviation-of-cd8-t-cells-in-mice
#14
Alison Hogg, Yongjun Sui, Shlomo Z Ben-Sasson, William E Paul, Jay A Berzofsky
The ability of different CD4(+) T cell subsets to help CD8(+) T-cell response is not fully understood. Here, we found using the murine system that Th17 cells induced by IL-1β, unlike Th1, were not effective helpers for antiviral CD8 responses as measured by IFNγ-producing cells or protection against virus infection. However, they skewed CD8 responses to a Tc17 phenotype. Thus, the apparent lack of help was actually immune deviation. This skewing depended on both IL-21 and IL-23. To overcome this effect, we inhibited Th17 induction by blocking TGF-β...
July 24, 2017: European Journal of Immunology
https://www.readbyqxmd.com/read/28735080/recombinant-truncated-e-protein-as-a-new-vaccine-candidate-against-nontypeable-h-%C3%A2-influenzae-its-expression-and-immunogenic-evaluation
#15
Ava Behrouzi, Saeid Bouzari, Farzam Vaziri, Abolfazl Fateh, Parviz Afrough, Atefeh Davoudi Vijeh Motlagh, Seyed Davar Siadat
Protein E (PE) is a conserved entity observed in both nontypeable Haemophilus influenzae (NTHi) and encapsulated H. influenzae. This is a small surface lipoprotein, consisting of only 160 amino acids, involved in the adhesion of H. influenzae to various types of epithelial cells. A 384-bp-long fragment from NTHi PE was cloned into the prokaryotic expression vector pBAD-gIIIA. The recombinant protein was expressed with arabinose and then purified by affinity purification on an Ni-NTA agarose matrix. BALB/c mice were immunized by subcutaneous injection with purified recombinant truncated PE mixed with an alum adjuvant...
July 19, 2017: Microbial Pathogenesis
https://www.readbyqxmd.com/read/28734174/old-and-new-adjuvants
#16
REVIEW
Amy S McKee, Philippa Marrack
Adjuvants have been deliberately added to vaccines since the 1920's when alum was discovered to boost antibody responses, leading to better protection. The first adjuvants were discovered by accident and were used in the safer but less immunogenic subunit vaccines, supposedly by providing an antigen depot to extend antigen presentation. Since that time, much has been discovered about how these adjuvants impact cells at the tissue site to activate innate immune responses, mobilize dendritic cells and drive adaptive immunity...
July 19, 2017: Current Opinion in Immunology
https://www.readbyqxmd.com/read/28728074/no-pain-no-gain-adjuvant-effects-of-alum-and-monophosphoryl-lipid-a-in-pertussis-and-hpv-vaccines
#17
REVIEW
Thomas C Mitchell, Carolyn R Casella
Development of non-infectious subunit vaccines is hampered by a slow pipeline of new adjuvants to replace or enhance alum in part because expectations of safety are high. Transient vaccine side effects are not clinical priorities because they cause no lasting harm and vaccine development has appropriately been focused on avoidance of serious adverse events. As a result, surprisingly little is known about the extent to which side effects caused by a vaccine's reactogencicity are predictive of successful immunization outcomes...
July 17, 2017: Current Opinion in Immunology
https://www.readbyqxmd.com/read/28719287/phase-1-randomized-study-of-a-tetravalent-dengue-purified-inactivated-vaccine-in-healthy-adults-in-the-united-states
#18
RANDOMIZED CONTROLLED TRIAL
Alexander C Schmidt, Leyi Lin, Luis J Martinez, Richard C Ruck, Kenneth H Eckels, Alix Collard, Rafael De La Barrera, Kristopher M Paolino, Jean-François Toussaint, Edith Lepine, Bruce L Innis, Richard G Jarman, Stephen J Thomas
AbstractThe safety and immunogenicity of four formulations of an investigational tetravalent dengue purified inactivated vaccine (DPIV), formulated at 1 or 4 μg with aluminum hydroxide (alum) or at 1 μg with an adjuvant system (AS01E or AS03B), were evaluated in a first-time-in-human, placebo-controlled, randomized, observer-blind, phase 1 trial in the continental United States. Two doses of vaccine or placebo were administered intramuscularly 4 weeks apart to 100 healthy adults 18-39 years of age, randomized 1:1:1:1:1 to receive one of four DPIV formulations or saline placebo...
June 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28718065/structure-function-relationships-of-protein-lipopeptide-complexes-and-influence-on-immunogenicity
#19
Acep R Wijayadikusumah, Lucy C Sullivan, David C Jackson, Brendon Y Chua
The lipopeptide, R4Pam2Cys, associates electrostatically with soluble protein antigens and significantly enhances their ability to induce protective humoral and cell-mediated responses. We demonstrate that antibody titers elicited by the antigen ovalbumin (OVA) associated with R4Pam2Cys are higher than those elicited by OVA in the presence of alum and comparable to those elicited by OVA formulated with complete Freund's adjuvant (CFA). The hierarchy of anti-OVA antibody avidities was CFA > R4Pam2Cys = alum...
July 17, 2017: Amino Acids
https://www.readbyqxmd.com/read/28716554/calcium-phosphate-nanoparticle-capnp-for-dose-sparing-of-inactivated-whole-virus-pandemic-influenza-a-h1n1-2009-vaccine-in-mice
#20
Tülin Morçӧl, Brett L Hurst, E Bart Tarbet
The emergence of pandemic influenza strains, particularly the reemergence of the swine-derived influenza A (H1N1) in 2009, is reaffirmation that influenza viruses are very adaptable and influenza remains as a significant global public health treat. As recommended by the World Health Organization (WHO), the use of adjuvants is an attractive approach to improve vaccine efficacy and allow dose-sparing during an influenza emergency. In this study, we utilized CaPtivate Pharmaceutical's proprietary calcium phosphate nanoparticles (CaPNP) vaccine adjuvant and delivery platform to formulate an inactivated whole virus influenza A/CA/04/2009 (H1N1pdm) vaccine as a potential dose-sparing strategy...
August 16, 2017: Vaccine
keyword
keyword
50339
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"